Abstract | BACKGROUND AND OBJECTIVES: METHODS: Twenty subjects suffering from neuropathic pain with prominent allodynia were enrolled in a randomized placebo-controlled crossover study. Patients were titrated to a maximum dose of 900 mg/d or dose-limiting side effects, whichever occurred first. At baseline and on days 0, 4, 7, and 10, the following tests were performed: (1) Quality of Life Questionnaires; (2) pain scores; (3) area of allodynia; (4) side effects; (5) neurosensory testing; and (6) peak and trough plasma mexiletine levels. RESULTS: Peak plasma levels occurred on day 10 and were 0.54 microg/mL. There was no significant effect on any quality of life measurement. There was no significant effect on any neurosensory threshold or the area of allodynia. There was a significant effect of mexiletine on stroking-induced pain. There were no significant effects on any other pain score. Side effects were negligible. CONCLUSIONS:
|
Authors | M S Wallace, S Magnuson, B Ridgeway |
Journal | Regional anesthesia and pain medicine
(Reg Anesth Pain Med)
2000 Sep-Oct
Vol. 25
Issue 5
Pg. 459-67
ISSN: 1098-7339 [Print] England |
PMID | 11009230
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Sodium Channel Blockers
- Mexiletine
|
Topics |
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Cross-Over Studies
- Double-Blind Method
- Female
- Humans
- Male
- Mexiletine
(adverse effects, blood, therapeutic use)
- Middle Aged
- Pain
(drug therapy, psychology)
- Pain Threshold
(drug effects)
- Quality of Life
- Sodium Channel Blockers
|